<DOC>
	<DOCNO>NCT01053390</DOCNO>
	<brief_summary>Objective Primary : Determine objective response rate patient advance gallbladder treat new Chemotherapy regimen Secondary : Determine time progression-free survival overall survival patient treat regimen . Determine quality life patient treat regimen . Determine toxicity new chemotherapy regimen</brief_summary>
	<brief_title>New Chemotherapy Regimen Treatment Advanced Gallbladder Carcinoma</brief_title>
	<detailed_description>Study Design : Treatment , Randomized , Open Label , control , Multicenter Group Assignment , Safety/Efficacy Study Chemotherapy regimen : Group A : Conventional chemotherapy regimen Group B : New chemotherapy regimen : conventional regimen plus SST（somatostatin） Cycles repeat every 4 week 6 cycle total Patients : A total 260 patient ( 130 per group ) accrue study . Patients distribution : 10patients per center enrol study 30 center ( hospital ) total meet total number patient trial . Clinical Outcome Assessments : Primary : objective response rate ( response evaluation criterion solid tumor , RECIST criterion ) Secondary : progression-free survival , overall survival , quality life，the adverse event Safety Assessments : Physical exam , laboratory test , probably occur adverse event .</detailed_description>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>1 . Patients unresectable locally advanced disease unresectable local recurrence , include : Patients unresectable advanced gallbladder cancer （≥ Nevin stag IV TNM（ tumor node metastasis） classification） Patients complication indication surgery Patients unresectable local recurrence lesion 2 . Age 1875 , genderbased constraint 3 . Estimated life expectancy ≥12 week 4 . KPS（Karnofsky performance status ）≥60 5 . Each patient give write informed consent 6 . &lt; 2 previous chemotherapy regimes 7 . No chemotherapy do last 4 week 8 . Laboratory test criterion : Haemoglobin ≥ 10g/dl , white blood cell count &gt; 3,000/mm3 ; Platelet &gt; 100,000/mm3 Total bilirubin &lt; 5.0mg/dl ALT（alanine transaminase）、 AST（aspartate aminotransferase ) ≤ 2.5 time upper limit normal BUN（blood urea nitrogen）≤ 2 time upper limit normal ; serum creatinine &lt; 1.5mg/dl : creatinine clearance rate &lt; 60 ml/min 9 . Patients require histologically confirm diagnosis via puncture base least computed tomography ( CT ) ultrasound 10 . Jaundice reduce standard level chemotherapy ( Total bilirubin &lt; 5.0 mg/dl ) 1 . Patients extensive metastasis generally poor condition tolerate chemotherapy 2 . Patients pregnant breastfeeding . 3 . Patients clinically significant laboratory abnormality , uncontrolled infection , concurrent severe medical problem unrelated malignancy 4 . Patients history previous carcinoma last 5 year . 5 . Patients allergic somatostatin fluorouracil 6 . Patients refuse chemotherapy , sign inform consent chemotherapy consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>gallbladder neoplasmas</keyword>
	<keyword>Gallbladder Neoplasms , Advanced Stage , Chemotherapy , Somatostatin</keyword>
</DOC>